BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dotan I, Levy-Nissenbaum E, Chowers Y, Fich A, Israeli E, Adar T, Shteingart S, Soreq H, Goldin E. Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. Dig Dis Sci 2016;61:3246-54. [PMID: 27572942 DOI: 10.1007/s10620-016-4276-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Marafini I, Monteleone G. Inflammatory bowel disease: new therapies from antisense oligonucleotides. Ann Med 2018;50:361-70. [PMID: 29911450 DOI: 10.1080/07853890.2018.1490025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
3 Yamamoto-Furusho JK, Parra-Holguín NN. Emerging therapeutic options in inflammatory bowel disease. World J Gastroenterol 2021; 27(48): 8242-8261 [DOI: 10.3748/wjg.v27.i48.8242] [Reference Citation Analysis]
4 Porter RJ, Andrews C, Brice DP, Durum SK, McLean MH. Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease? Inflamm Bowel Dis 2018;24:2123-34. [PMID: 30020451 DOI: 10.1093/ibd/izy230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Corridoni D, Chapman T, Ambrose T, Simmons A. Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease. Front Med (Lausanne) 2018;5:32. [PMID: 29515999 DOI: 10.3389/fmed.2018.00032] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
6 Bevivino G, Sedda S, Marafini I, Monteleone G. Oligonucleotide-Based Therapies for Inflammatory Bowel Disease. BioDrugs 2018;32:331-8. [PMID: 29948918 DOI: 10.1007/s40259-018-0286-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Scarozza P, Schmitt H, Monteleone G, Neurath MF, Atreya R. Oligonucleotides-A Novel Promising Therapeutic Option for IBD. Front Pharmacol 2019;10:314. [PMID: 31068803 DOI: 10.3389/fphar.2019.00314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]